Last reviewed · How we verify
NCT03413176: VEGAN
Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.
trial testing Cardiac complication induced by VEGF/VEGFR inhibitor in Cardiac Complication in 150,000 participants. Completed in 31 January 2018.
15 January 2018
Quick facts
| Lead sponsor | Groupe Hospitalier Pitie-Salpetriere |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 150,000 |
| Start date | 1 January 2018 |
| Primary completion | 15 January 2018 |
| Estimated completion | 31 January 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- Cardiac complication induced by VEGF/VEGFR inhibitor — full drug profile →
Conditions studied
- Cardiac Complication — all drugs for Cardiac Complication →
- Vascular Diseases — all drugs for Vascular Diseases →
Sponsor
Groupe Hospitalier Pitie-Salpetriere
Who can join
18 and older, any sex, with Cardiac Complication or Vascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Antiangiogenics (AAs) which are vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR) inhibitors might have high grade adverse events (AEs) on the cardio-vascular system. This study investigates reports of cardio-vascular toxicity with treatment including VEGF and VEGFR inhibitors using the World Health Organization (WHO) database VigiBase.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03413176
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiac Complication
Currently open trials in the same condition.
- NCT07059624 — Femoral Arterial Cannulation in Pediatrics · NA · recruiting
- NCT03209674 — Registry for the Improvement of Postoperative OutcomeS in Cardiac and Thoracic surgEry · recruiting
Other Groupe Hospitalier Pitie-Salpetriere trials
Trials by the same sponsor.
- NCT06515678 — Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension · active not recruiting
- NCT05934214 — EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Databa · completed
- NCT05819736 — Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients · unknown
- NCT04320017 — Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observa · completed
- NCT04314817 — Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03413176 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier Pitie-Salpetriere
- Last refreshed: 26 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03413176.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing